ALNYLAM PHARMACEUTICALS, INC. — Form 10-Q
Filed July 30, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Yvonne L. Greenstreet (CEO) and Jeffrey V. Poulton (CFO) issued standard Sarbanes-Oxley certifications dated July 30, 2026 for Alnylam's Q2 2026 10-Q (quarter ended June 30, 2026). Both officers certified that the report contains no material misstatements, financial statements fairly present results, and internal controls over financial reporting are effective. No specific transactions, dollar amounts, or material changes are disclosed in these certification exhibits.
Why this rating
Routine SOX certifications are standard quarterly filings; no material transactions, control failures, or business changes reported here.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.